Lonquex (lipegfilgrastim biosimilar) / Teva 
Welcome,         Profile    Billing    Logout  
 18 Diseases   3 Trials   3 Trials   118 News 


12»
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    PEGFILGRASTIM FOR STEM CELL MOBILIZATION FOLLOWED BY FRESH STEM CELL INFUSION IN MULTIPLE MYELOMA (CLYDE) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2232;    
    Health resource utilization reduced modestly with PEG during mobilization. Transplant short term outcomes were comparable without the requirement of GCSF to hasten neutrophil engraftment, and with a reduction in the transfusion requirements needs in the PEG group.
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    PEGFILGRASTIM FOR STEM CELL MOBILIZATION FOLLOWED BY FRESH STEM CELL INFUSION IN MULTIPLE MYELOMA (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2231;    
    Health resource utilization reduced modestly with PEG during mobilization. Transplant short term outcomes were comparable without the requirement of GCSF to hasten neutrophil engraftment, and with a reduction in the transfusion requirements needs in the PEG group.
  • ||||||||||  Lonquex (lipegfilgrastim biosimilar) / Teva
    Journal, Real-world evidence:  A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe. (Pubmed Central) -  Nov 8, 2022   
    None of the SAEs was "fatal," and CTCAE grade was mostly (89.6%) assessed as "1" or "2." According to the treating physicians, 99.3% of all patients benefitted from lipegfilgrastim prophylaxis, and tolerability was mostly rated "very good" or "good." These results suggest that primary lipegfilgrastim prophylaxis is effective and safe in clinical routine and is beneficial in primary breast cancer patients undergoing dd/idd-ETC CTx. Using real-world data, these findings confirm the low rate of lipegfilgrastim off-label use as reported in a preceding feasibility study, indicating very high adherence to the approved indication.
  • ||||||||||  Lonquex (lipegfilgrastim biosimilar) / Teva
    Journal:  Lipegfilgrastim may cause hyperleukocytosis. (Pubmed Central) -  Nov 2, 2022   
    In patients with lymphoma, neutropenia event-related healthcare costs and all-cause hospitalizations were significantly higher with pegfilgrastim compared with lipegfilgrastim in this study; however, this should be interpreted with caution in light of the limited sample size and the absence of clinical information. Although lipegfilgrastim-induced hyperleukocytosis has not been reported in the literature, it should be borne in mind that hyperleukocytosis and related complications may occur, as in our case.
  • ||||||||||  Lonquex (lipegfilgrastim biosimilar) / Teva
    Clinical, Journal:  Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients. (Pubmed Central) -  Sep 1, 2021   
    As lipegfilgrastim is administered only once, it is conceivable that it improves both compliance and quality-of-life (NCT02488382). Administration of lipegfilgrastim in routine clinical practice in the Netherlands results in limited CT/BT dose modifications and low incidence of neutropenic events, with no new safety concerns.
  • ||||||||||  Lonquex (lipegfilgrastim biosimilar) / Teva
    [VIRTUAL] SPLENIC INCREASED 18F-FDG UPTAKE IN PET SCAN PERFORMED FOLLOWING TREATMENT WITH PEG-GCSF LIPEFILGASTRIM () -  Jun 11, 2021 - Abstract #ICML2021ICML_659;    
    it is important to know that in pts who received aggressive chemoteraphy protocol like HL and NHL associated with a Lipegfilgastrim can have therapeutic-related reactive splenic uptake concurrent with bone marrow uptake secondary to administration of G-CSF for myelosuppression without influencing on the Deauville score determination. We think that the type of G-CSF used, the time elapsed between its last injection and interim PET/CT and the time-lapse between the chemotherapy and the PET/ CT examination must be evaluated when performing a 18F-FDG PET scan, to avoid false-positive results.
  • ||||||||||  Lonquex (lipegfilgrastim biosimilar) / Teva
    Journal:  Lipegfilgrastim - long acting G-CSF in prevention of chemotherapy-induced neutropenia (Pubmed Central) -  Nov 14, 2019   
    The oncologists can reach treatment success in the patient's therapy if he or she provides the patient the adequate supportive medications at the appropriate time. Lipegfilgrastim is not a biosimilar, but a new molecule created by a two-step empiric glycopegylation process.
  • ||||||||||  Lonquex (lipegfilgrastim biosimilar) / Teva
    Clinical, Journal:  Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe. (Pubmed Central) -  May 21, 2019   
    While recruitment was challenging, the results of this pilot study confirm the feasibility and availability of medical records and the use of pharmacists as abstractors to assess on- and off-label use of lipegfilgrastim. Lipegfilgrastim was mainly prescribed according to the approved indications.Key pointsFindings from this pilot study confirm the feasibility and availability of medical records and the use of pharmacists as abstractors to assess on-label and off-label use of lipegfilgrastim in routine clinical practice.Lipegfilgrastim was mainly prescribed according to the approved indications, and the proportion of off-label use was low.The high inter-rater agreement between the two abstractors suggests that one abstractor is sufficient for conducting chart abstraction of on- and off-label use.Additional data abstraction sources other than pharmacists will need to be identified to improve response rate and center recruitment.Findings from this pilot study are important for the successful planning and execution of subsequent drug utilization studies.
  • ||||||||||  Lonquex (lipegfilgrastim biosimilar) / Teva
    Trial completion, Trial completion date, Trial primary completion date:  Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer (clinicaltrials.gov) -  Feb 9, 2018   
    P=N/A,  N=40, Completed, 
    Trial completion date: May 2018 --> Apr 2018 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2018 | Trial completion date: Jul 2017 --> Feb 2018